Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbl JD, Hansen T et al (2017) Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
In a previous trial published in December, retatrutide helped patients with obesity and osteoarthritis of the knee lose an average of 28.7 per cent of their weight over 40 weeks and reduce knee pain
Dosing and formulation complexity: Trial drugs are delivered in exact formulations and regimens
Who Benefits Most From Microdose Semaglutide Therapy
Overweight is defined as having a body mass index (BMI) between 25 and 30, while obesity is defined as a BMI of 30 or higher
The indications of Ozempic and Victoza are pretty similar